The aim of thrombolysis, angioplasty, and coronary artery bypass surgery is to "reperfuse" ischemic myocardium; however, reperfusion can cause further cardiac damage and compromise the coronary microcirculation. Because nutrient supply and exchange and delivery of pharmacologic agents require a patent microvasculature, the coronary microcirculation plays a major role in myocardial recovery from ischemia. It is known that ischemia-reperfusion can cause an increase in coronary permeability and microvascular plugging (No-reflow). The permeability to macromolecules is increased more than the permeability to smaller molecules. The permeability increase leads to extravasation of plasma proteins and a permeability edema. Furthermore, proteins that normally remain extravascular are now free to wash out the heart. Both microvascular effects, increased coronary permeability and No-reflow, compromise cardiac function. The degree of damage depends on the nature (No-flow versus low-flow) and length of ischemia. Unfortunately, both the increase in coronary permeability and the reduction in perfused capillarity advance with time during early reperfusion. Although the increase in permeability does not require the presence of platelets or leukocytes, it is apparent that the No-reflow response does. Mechanisms that may explain the microvascular responses to ischemia include cell swelling, damage caused by oxygen free radicals, and inflammatory responses that may or may not involve granulocytes. The permeability response may involve a calcium-mediated endothelial contraction because the macromolecular leakage that follows ischemia can be prevented by pretreating hearts with the calcium blocker nisoldipine. Protection of the coronary microcirculation should be included in any attempt to improve treatment of occlusive coronary artery disease.